Excluding the aforementioned signs and symptoms of the chief complaint, the patient's physical examination was unremarkable. Imaging studies, which included chest radiography, a computed tomography scan of the chest, the abdomen, and the neural axis, as well as a transthoracic echocardiogram, did not reveal any abnormalities. However, ultrasound examination of the abdomen revealed fatty liver disease, which is a marker of metabolic syndrome.
In the course of the disease, the patient underwent multiple regimens of multimodal therapy involving non-steroidal anti-inflammatory drugs, tricyclic antidepressants, baclofen, loratadine, lidocaine infusions, and opioids. With the exception of opioids, differing regimens composed of the aforementioned drugs resulted in moderate pain relief (from 8/10 to 5/10 on the numeric pain scale), although this relief was accompanied by the side effects that were typical for each drug. The side effects were not tolerated by the patient, and they developed fully over 2-3 months of each regimen. Only opioids resulted in significant pain relief (decrease in pain intensity from 8/10 to 2/10 on the numeric pain scale). However, the salutatory effects of the opioids were limited by the development of opioid tolerance over the period of 2-3 months, and an increase in the dosage did not result in further reductions in pain. The patient was disappointed with the effects of the various analgesic regimens he was on and discontinued their use 6 months prior to his presentation. The only medications the patient was taking were bisoprolol (2.5 mg/day), aspirin (75 mg/day), and pantoprazole (40 mg/day).
On presentation, the patient was screened for and diagnosed with type 2 diabetes, which allowed us to initiate metformin therapy. The intervention did not diminish the number of painful lipomas; however, it did lower the intensity of the pain to 1-2/10, 1/10, and 1-2/10, during the visit, during the previous week, and over the course of the previous month, respectively. This remarkable effect was achieved in 3 months, starting from 500 mg of metformin to 850 mg of metformin three times daily and has now lasted for over a year. The improvement in the patient's symptoms was paralleled by a favorable change in his serum biochemical markers (Table 1) . Moreover, the patient reported a diminished daily requirement of pain relievers, which were prescribed for breakthrough pain. He also reported increased efficacy of oral morphine (20 mg/day).
Insulin resistance and type 2 diabetes mellitus are ubiquitous among patients with Dercum's disease [2] . From this point of view, insulin resistance may be considered a part of the syndrome. Furthermore, there is a substantial interplay between insulin resistance, inflammation, and the biology of pain. In our patient, metformin controlled his diabetes, as evidenced by improved levels of fasting glycemia, glycated hemoglobin (from 6.8% to 6.2%), and markers of inflammation (Table 1) . Therefore, management of insulin resistance with metformin may be a useful intervention in patients with Dercum's disease.
Beta-endorphin is a major neurotransmitter and a m-receptor agonist in the pain descending inhibitory system [3] . Recent findings support the role of betaendorphin in the insulin-sensitizing effects of metformin. Metformin was shown to enhance beta-endorphin secretion from adrenal glands, which stimulates opioid m-receptor linkage, leading to an increase of glucose Ethical considerations: Written consent was obtained from the patient for publication of this study. Conflicts of interests: The author(s) declare that they have no conflicts of interests. transporter type 4 gene expression and an attenuation of hepatic phosphoenolpyruvate carboxykinase gene expression in streptozotocin-induced diabetic rats. Both a knockout of the m-receptor and antagonism with naloxone and naloxazine abated metformin's effects in a mouse model [4] . Decreased insulin sensitivity, or insulin resistance, is associated with a decreased concentration of beta-endorphin in human plasma [5] , and infusion of exogenous beta-endorphin ameliorates this abnormality in fructose-fed rats [6] . Importantly, metformin-mediated improvements in insulin sensitivity, as assessed using the homeostasis model of assessment-insulin resistance, correlated with increased plasma concentrations of beta-endorphin in healthy volunteers [5] . Therefore, the observed increase of beta-endorphin levels in our patient's plasma appears to be neither a coincidence nor a placebo effect.
In conclusion, we present this case to suggest that insulin resistance may exacerbate chronic pain syndromes and that management of this resistance with metformin may improve pain symptoms in this subpopulation of patients. However, we cannot exclude that metformin, based on its pharmacodynamics, may have co-analgetic and opioidsparing properties.
